Renal Cell Carcinoma

The frontline combination of lenvatinib and pembrolizumab is under investigation as a treatment option for patients with non-clear cell renal cell carcinoma in the recently launched phase 2 KEYNOTE-B61 trial.

While immunotherapy has high and durable response rates, most patients die of the disease.

Savolitinib in combination with durvalumab has been dosed to the first patient with MET-driven advanced papillary renal cell carcinoma in a phase 3 study.

During a presentation at the 2021 International Kidney Cancer Symposium, Bradley McGregor, MD, discussed analyses of outcomes based on histology in major RCC clinical trials, and how this approach will shape the future of treatment.

Naomi B. Haas, MD, medical oncologist, discusses the potential benefits of lenvatinib for the treatment of renal cell carcinoma.

Limited data exists on the effects of palliative care in patients with kidney cancer, and more research is needed.

Sarah P. Psutka, MD, discusses the key findings of a retrospective study of the efficacy of Immune checkpoint inhibitor plus tyrosine kinase inhibitor as any-line treatment for patients with renal cell carcinoma.

Retrospective data suggest that perinephric fat invasion, sarcomatoid or rhabdoid component, and necrosis are independent prognostic indicators of recurrence-free survival in renal cell carcinoma.

Sarah P. Psutka, MD, discussed the efficacy and toxicity of later-line ICI and TKI therapy in mRCC during an interview with Targeted Oncology.

Sarah P. Psutka, MD, discusses the efficacy of the combination of immune checkpoint inhibitor therapy plus tyrosine kinase inhibitor for the treatment of metastatic renal cell carcinoma.

Jeffrey A. Sosman, MD leads a discussion about a 59-year-old Black who woman received a diagnosis of clear cell renal cell carcinoma.

Results shared in a webinar during the 2021 European Association of Urology Congress show the potential of adjuvant pembrolizumab for the treatment of renal cell carcinoma.

Chung-Han Lee, MD, PhD, discusses the phase 2 KEYNOTE-B61 trial of pembrolizumab plus lenvatinib in patients with non–clear cell renal cell carcinoma.

Cabozantinib is a feasible perioperative treatment and induced responses in patients with intermediate and poor-risk metastatic renal cell carcinoma.

While they may differ by other genetic alterations, patients with VHL mutated clear cell renal cell carcinoma or VHL wild type ccRCC may have similar characteristics.

A lack of understanding about renal cell carcinoma (RCC), clinical trials, and the diseases psychosocial impact may exist in patients living with the illness and their families.

While the benefit is yet to be determined in those with favorable-risk disease, patients with advanced renal cell carcinoma experienced improvements in both progression-free and overall survival after being treated with first-line immunotherapy vs sunitinib.

In season 2, episode 8 of Targeted Talks, Thomas Hutson, DO, PharmD, and Rana R. McKay, MD, discuss the renal cell carcinoma paradigm and challenges to overcome in the future.

An impressive disease-free survival benefit was seen in patients with clear cell renal cell carcinoma with pembrolizumab as an adjuvant therapy following nephrectomy compared with placebo. This improvement was observed across subgroups.

Roughly 50% of patients with clear cell renal cell carcinoma responded to the combination of nivolumab plus ipilimumab in a Japanese study, and varied responses occurred in those with nonclear cell histology.

Nizar M. Tannir, MD, FACP, discusses why telaglenastat in combination with cabozantinib did not improve efficacy in compared with cabozantinib alone in patients with metastatic renal cell carcinoma.

A diagnosis of stage IV renal cell carcinoma in a 59-year-old- African American patient was the topic of a discussion led by Christopher W. Ryan, MD.

The FDA has approved belzutifan for the treatment of von Hippel-Lindau-associated renal cell carcinoma treated in frontline setting.

The FDA has granted approval to the combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).

The FDA has accepted a supplemental biologics license application for adjuvant pembrolizumab and granted it priority review as a treatment for patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.